The iconic rise of Viagra has firmly established as a benchmark of pharmaceutical success, however its future within the broader industry now presents questions about potential yields . Copycat versions are diminishing market share, prompting concerns that betting on companies heavily reliant to Viagra's previous standing could be a problematic mov